Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 3/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | POLR1A | O95602 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975469 | 0.85 | PTPRC (0.41) | USP30MEN1KMT2A | |
| SCHEMBL3403687 | 0.84 | CTSD (0.38) | USP30MEN1KMT2ACTSDBACE1 | |
| SCHEMBL975683 | 0.84 | CTSD (0.37) | USP30MEN1KMT2ACTSDBACE1 | |
| SCHEMBL977097 | 0.83 | HSP90AA1 (0.39) | USP30MEN1KMT2A | |
| SCHEMBL2166581 | 0.83 | NPC1 (0.40) | USP30MEN1KMT2ACTSDBACE1 | |
| Hydrochloric Acid SCHEMBL2166836 | 0.83 | USP30 (0.43) | USP30ANO1MEN1KMT2ABACE1 | |
| SCHEMBL2166240 | 0.82 | NPC1 (0.40) | USP30MEN1KMT2ACTSDBACE1 | |
| SCHEMBL2166243 | 0.82 | NPC1 (0.40) | USP30CTSDBACE1BACE2 | |
| SCHEMBL3408730 | 0.82 | DDR1 (0.36) | MEN1KMT2ACTSDBACE1BACE2 | |
| SCHEMBL977045 | 0.81 | CACNA2D1 (0.41) | MEN1KMT2ACTSDBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183961-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | claimed |
| US-20110183961-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183961-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, C1S, TACR1 | USP30 2594/4885ANO1 429/4885MEN1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.